Improving how the body heals after injury using targeted medicine
Designing supramolecular delivery strategies to understand and exploit synergies in immunoregenerative medicine
This project aims to understand how our immune system helps tissues heal or scar, especially in conditions like heart disease, by using special delivery systems for medicines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Drexel University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11125870 on NIH RePORTER |
What this research studies
When our bodies get injured, sometimes tissues heal perfectly, and other times they form scars, and we want to understand why this happens. The immune system plays a big part in this process, with different cells working together to guide how tissues recover. Our team is creating new ways to deliver medicines directly to injured areas to help control the immune response. We are particularly interested in how these targeted medicines can encourage healing cells, called macrophages, to promote regeneration and prevent inflammation from getting worse. Ultimately, we hope to find better ways to help tissues heal and stop diseases like heart disease from progressing.
Who could benefit from this research
Good fit: This research is foundational and could eventually benefit patients experiencing tissue damage or inflammatory diseases, such as those with atherosclerotic cardiovascular disease.
Not a fit: Patients seeking immediate treatment options would not directly benefit from this early-stage research, as it focuses on fundamental biological mechanisms and drug delivery strategies.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that help tissues regenerate more effectively and reduce scarring in conditions like atherosclerotic cardiovascular disease.
How similar studies have performed: While the general concept of immune modulation for healing is explored, this specific approach of using supramolecular delivery to understand and exploit synergies in immunoregenerative medicine is novel.
Where this research is happening
Philadelphia, United States
- Drexel University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rodell, Christopher B — Drexel University
- Study coordinator: Rodell, Christopher B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.